RIPK1 and early-onset autosomal dominant Alzheimer disease: Furthermore, inhibiting RIPK1 activation alleviated neuroinflammation and cognitive impairments during Alzheimer’s disease, and didn’t show obvious toxic effect (Ofengeim et al., 2017; Yang et al., 2017).